USPTO serial 79379490
ELASMOGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 19, 2024
- Examiner
- MICKLEBURGH, LINDA BOHANNON
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ELASMOGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Charlene M. Krogh
Charlene M. Krogh Dorsey & Whitney LLP1400 Wewatta Street, Suite 400Denver, CO 80202-5549United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; biological preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations agents, and substances for medical purposes; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; diagnostic reagents for medical use; DNA, antibodies and proteins for medical diagnosis purposes; DNA and antibodies and proteins that stimulate cells for medical use; DNA, antibodies and proteins for therapeutic use for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; diagnostic preparations for medical purposes; reagents for medical use | ACTIVE | — |
| 042 | Medical and pharmacological research services; scientific and technological services, namely scientific research, analysis and testing in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; scientific research for medical purposes in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; pharmaceutical research and drug development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology research services; scientific research in the nature of conducting clinical trials for others; biological research, clinical research and medical research; providing scientific information about the results of clinical trials for pharmaceutical products; research services in the field of diagnostic preparations; scientific laboratory services; custom design and development of biochemical assays; scientific and medical research laboratory services; research and development of new products for others; scientific research and analysis in the field of drug discovery; new product development in the field of pharmaceuticals for others; scientific advisory services, namely, medical advisory services related to pharmaceutical development and testing; scientific research consultancy in the field of cancer research, inflammatory disease research, auto-inflammatory disease research, autoimmune disease research, eye disease and disorder research, and intracellular delivery research of pharmaceuticals and therapeutics; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; consulting services for others in the field of design, planning, and implementation and project management of scientific research and clinical trials; providing scientific research information; technical advisory services relating to scientific and clinical research; provision of technical and scientific information and consultancy in relation to the aforesaid services. | ACTIVE | — |
| 044 | Medical services; medical advisory services relating to the treatment, relief and prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro-intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; preparation and provision of medical reports to patients and medical professionals; preparation and provision of medical information in the form of reports on pharmaceuticals, advanced therapy medicinal products, and therapeutic antibodies to patients and medical professionals; consultancy, advice and information in the field of healthcare, pharmaceuticals and advanced therapy medicinal products | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Elasmogen Ltd
- Other trademarks owned by Elasmogen Ltd
- Other trademarks owned by Elasmogen Ltd
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ELASMOGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 3, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 16, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 16, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 14, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 27, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 27, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 19, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 19, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 19, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 3, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 3, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 14, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 31, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 29, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 29, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 29, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 19, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 1, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 1, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 18, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 17, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 17, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 3, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 29, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 28, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |